JAK2 inhibitors for the treatment of myeloprolifertive disorders.

被引：2
|
作者：
Hood, John [1 ]
Cao, Jon [1 ]
Hanna, Ehab [1 ]
Lohse, Dan [1 ]
Mak, Chi Ching [1 ]
McPherson, Andrew [1 ]
Noronha, Glenn [1 ]
Renick, Joel [1 ]
Zheng, Binqi [1 ]
Zhu, Hong [1 ]
Soll, Richard [1 ]
机构：
[1] Res & Dev, San Diego, CA USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.3632.3632
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3632
引用
收藏
页码：1038A / 1038A
页数：1
相关论文
共 50 条
  • [21] Preclinical characterization of JAK1/JAK2 inhibitors for treatment of type 1 diabetes
    Scott, N. A.
    Trivedi, P. M.
    Graham, K. L.
    Fynch, S.
    Jenkins, M. R.
    Kay, T. W.
    Thomas, H. E.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 361 - 361
  • [22] Heterogeneous distribution of the JAK2 Val617Phe activating mutation in familial myeloproliferative disorders.
    Bellanne-Chantelot, C
    Labopin, M
    Chaumarel, I
    Delhommeau, F
    Leroy, G
    Bellanger, F
    Thomas, G
    Vainchenker, W
    Najman, A
    BLOOD, 2005, 106 (11) : 38A - 38A
  • [23] Single nucleotide polymorphism (SNP) analysis of JAK2 and relevant cytokine receptor genes in myeloproliferative disorders.
    Pardanani, Animesh
    Fridley, Brooke
    Lasho, Terra
    Achenbach, Sara
    Gilliland, D. Gary
    Tefferi, Ayalew
    BLOOD, 2006, 108 (11) : 199A - 199A
  • [24] Therapy of myelofibrosis (excluding JAK2 inhibitors)
    Alessandro Rambaldi
    International Journal of Hematology, 2010, 91 : 180 - 188
  • [25] Targeting myeloproliferative diseases with JAK2 inhibitors
    Markovtsov, Vadim
    Yu, Diane
    Gelman, Marina
    Lang, Wayne
    Taylor, Vanessa C.
    Huynh, Stacey
    Frances, Roy
    Fang, Shilling
    McLaughlin, John
    Bhamidipati, Sohasekhar
    Clough, Jeffrey
    Singh, Rajinder
    Park, Gary
    Sweeney, David
    Tonkin, Elizabeth
    Bahjat, Rena
    Chang, Betty
    Pine, Polly
    Daniel, Ruby
    Payan, Donald G.
    Holland, Sacha
    Hitoshi, Yasurnichi
    BLOOD, 2007, 110 (11) : 1039A - 1039A
  • [26] Update on JAK2 inhibitors in myeloproliferative neoplasm
    Chan, Daniel
    Koren-Michowitz, Maya
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2011, 2 (02) : 61 - 71
  • [27] CEP-701 is a JAK2 inhibitor which attenuates JAK2/STAT5 signaling pathway and the proliferation of primary cells from patients with myeloproliferative disorders.
    Dobrzanski, Pawel
    Hexner, Elizabeth
    Serdikoff, Cynthia
    Jan, Mahfuza
    Swider, Cezary
    Robinson, Candy
    Yang, Shi
    Angeles, Thelma
    Emerson, Stephen G.
    Carroll, Martin
    Ruggeri, Bruce
    BLOOD, 2006, 108 (11) : 1026A - 1026A
  • [28] JAK2 inhibitors and their impact in myeloproliferative neoplasms
    Geyer, Holly L.
    Tibes, Raoul
    Mesa, Ruben A.
    HEMATOLOGY, 2012, 17 : S129 - S132
  • [29] Therapy with JAK2 Inhibitors for Myeloproliferative Neoplasms
    Santos, Fabio P. S.
    Verstovsek, Srdan
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2012, 26 (05) : 1083 - +
  • [30] New JAK2 inhibitors for myeloproliferative neoplasms
    Quintas-Cardama, Alfonso
    Verstovsek, Srdan
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (07) : 961 - 972
12345